Q-omics provides the consensus-scored C11orf65 profile across patient tissues and cancer cell-line models. C11orf65 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, C11orf65 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, C11orf65 RNA expression shows 19,903 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where C11orf65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C11orf65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C11orf65 survival associations across molecular data types. C11orf65 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C11orf65 RNA expression–survival associations across cancer types. High C11orf65 expression shows unfavorable associations in UVM and BLCA, but favorable associations in UCS, SKCM, SCLC and READ. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify UCS as the clearest survival context for C11orf65 RNA expression.
This table summarizes C11orf65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for C11orf65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C11orf65 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in COAD, LUSC and HNSC. The THCA box plot shows higher C11orf65 RNA expression in normal versus tumor tissue (log2 FC = −0.585, t-test p < 0.001).
This table shows molecular features associated with C11orf65 in patient tissues and cancer cell lines. In patient samples, C11orf65 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C11orf65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
